Stockscreener 앱 받기
12.23
2.70%
-0.345
Cullinan Therapeutics Inc 주식(CGEM)의 최신 뉴스
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks
What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat
Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada
Cullinan advances lupus treatment with new clinical trial - Investing.com
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India
Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times
Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com
Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics Advances Pipeline Despite $40.6M Loss; Maintains $639M Cash Position | CGEM Stock News - StockTitan
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan
Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat
FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat
Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Newco trend watch: Clusters of launches point to areas undergoing derisking - BioCentury
cullinan oncology, inc. Earnings dates - RTTNews
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat
Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat
Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com
Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan
How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News
Cullinan Therapeutics Inc [CGEM] Records 200-Day SMA of $17.94 - Knox Daily
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Algert Global LLC Reduces Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
The Potential Rise in the Price of Cullinan Therapeutics Inc (CGEM) following insiders activity - Knox Daily
Metric Deep Dive: Understanding Cullinan Therapeutics Inc (CGEM) Through its Ratios - The Dwinnex
Results from Cullinan Therapeutics Inc (CGEM) show potential - US Post News
Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News
Deerfield Management Company L.P. Series C Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex
CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle
Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Highlights of Current Entertainment News - Devdiscourse
1.80%
0.42%
자본화:
|
볼륨(24시간):